Biotech company Vertex Pharmaceuticals (NASDAQ: VRTX) will be announcing earnings results this Monday after market close. Here’s what to expect.
Vertex Pharmaceuticals beat analysts’ revenue expectations last quarter, reporting revenues of $3.33 billion, up 12.5% year on year. It was a strong quarter for the company, with full-year revenue guidance slightly topping analysts’ expectations.
Is Vertex Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Vertex Pharmaceuticals’s revenue to grow 11% year on year, in line with the 11% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Vertex Pharmaceuticals rarely misses Wall Street’s revenue estimates.
Looking at Vertex Pharmaceuticals’s peers in the therapeutics segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Biogen delivered year-on-year revenue growth of 10.6%, beating analysts’ expectations by 6.4%, and Gilead Sciences reported revenues up 6.8%, topping estimates by 6.3%. Biogen traded down 1.2% following the results while Gilead Sciences was up 4.1%.
Read our full analysis of Biogen’s results here and Gilead Sciences’s results here.
There has been positive sentiment among investors in the therapeutics segment, with share prices up 5.6% on average over the last month. Vertex Pharmaceuticals is up 9.7% during the same time and is heading into earnings with an average analyst price target of $571.46 (compared to the current share price of $553.72).
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
